Rh-catalyzed tunable defluorinative borylation
- 17 June 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 57 (58) , 7124-7127
Abstract
Described herein is a Rh-catalyzed tunable defluorinative borylation of allylic gem-difluorides to provide allylborylated monofluoroalkenes or homoallylborylated monofluoroalkenes with excellent Z/E selectivities. Completely different reaction paths were observed by slightly changing the reaction conditions. Allylborylated monofluoroalkenes were further converted into dihydroxyl-containing monofluoroalkenes.Keywords
Funding Information
- Jinan Science and Technology Bureau (2019GXRC021)
- National Natural Science Foundation of China (21971252, 21991122)
- Chinese Academy of Sciences (QYZDJSSWSLH049)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2019256)
This publication has 22 references indexed in Scilit:
- Rovafovir etalafenamide Nucleotide reverse transcriptase inhibitor Treatment of HIV-1 infectionDrugs of the Future, 2020
- Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug DesignJournal of Medicinal Chemistry, 2018
- Copper-Catalyzed Regioselective Monodefluoroborylation of Polyfluoroalkenes en Route to Diverse FluoroalkenesJournal of the American Chemical Society, 2017
- Access to Constrained Fluoropseudopeptides via Ring-Closing Metathesis of FluoroalkenesOrganic Letters, 2016
- Copper-catalyzed direct C–H fluoroalkenylation of heteroarenesOrganic & Biomolecular Chemistry, 2015
- Monofluorination of Organic Compounds: 10 Years of InnovationChemical Reviews, 2015
- Palladium‐Catalyzed Direct Synthesis of Organoboronic AcidsAngewandte Chemie International Edition, 2011
- Synthetic approaches to monofluoroalkenesChemical Society Reviews, 2011
- Potassium Organotrifluoroborates: New Perspectives in Organic SynthesisChemical Reviews, 2007
- Evolving role of ribonucleoside reductase inhibitors in hematologic malignanciesExpert Review of Anticancer Therapy, 2002